Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,824.99
-37.6785-2.02%
Number of Gainers:4
Number of Losers:15
Number of Flat:- -
PE:- -
High:1,862.69
Open:1,861.76
Low:1,823.97
Close:1,862.66
Volume:87.21M
Turnover:8.25B
Market Cap:1.48T
Float Cap:1.45T

Loading ...

Aethlon Medical Shareholders Expand Capital Structure Flexibility

TIPRANKS
·
2 hours ago

Novavax Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
2 hours ago

Aethlon Medical Holds Annual Shareholder Meeting

Reuters
·
2 hours ago

Pfizer Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
3 hours ago

EQ Resources (ASX:EQR) Could Be 44% Below Fair Value After Profit Turnaround

Simply Wall St.
·
4 hours ago

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
5 hours ago

Sector Update: Healthcare

MT Newswires Live
·
6 hours ago

Pfizer Sued by Florida Attorney General Over Alleged Deceptive Marketing Practices

MT Newswires Live
·
Yesterday

Florida sues Pfizer over COVID vaccine marketing

TIPRANKS
·
Yesterday

Florida Attorney General: Files Lawsuit Against Pfizer and Its CEO Albert Bourla

THOMSON REUTERS
·
Yesterday

Gilead Sciences Announces Dividend of R$ 0.2394442440 Per Unit for Brgildbdr 000

Reuters
·
Yesterday

Moderna Stock Gets Sell Call As Oncology Hopes Face Valuation Test

Simply Wall St.
·
Yesterday

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

THOMSON REUTERS
·
Yesterday

Coty Names Kara Langan General Manager, U.S. Consumer Beauty Division

Reuters
·
Yesterday

Pfizer says Phase 2 study of tilrekimig met primary endpoint

TIPRANKS
·
Yesterday

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Yesterday

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Yesterday

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Yesterday

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Yesterday

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Yesterday